Mariner’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Mariner’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-63	Closed	-$1.28K	–	3850
2026 Q1	$1.28K	Buy	+63	New	+$12.6K	﹤0.01%	3540
2025 Q4	–	Sell	-612	Closed	-$200K	–	3754
2025 Q3	$200K	Hold	612	–	–	﹤0.01%	3180
2025 Q2	$202K	Hold	612	–	–	﹤0.01%	3049
2025 Q1	$163K	Hold	612	–	–	﹤0.01%	3069
2024 Q4	$229K	Hold	612	–	–	﹤0.01%	2888
2024 Q3	$95.1K	Buy	612 +242	+65%	+$34.7K	﹤0.01%	3100
2024 Q2	$55.6K	Hold	370	–	–	﹤0.01%	3036
2024 Q1	$78.5K	Hold	370	–	–	﹤0.01%	2973
2023 Q4	$77.8K	Sell	370 -5	-1%	-$1K	﹤0.01%	2893
2023 Q3	$84.1K	Buy	+375	New	+$98K	﹤0.01%	2705

Other funds holding IRLA

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Mariner's IRLA Position: Q2 2026 in Review

Mariner sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2026, closing a stake of 63 shares — an estimated $1.28K sold.

Mariner first reported a position in IRLA in Q3 2023 and held it in 10 quarters. The position peaked at $229K in Q4 2024. 26 funds tracked by Wall St. Rank hold IRLA as of Q2 2026.

Mariner reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q2 2026 after selling out during the quarter.
Mariner sold 63 IRulya Therapeutics Inc. Common Stock shares in Q2 2026, an estimated $1.28K.
Mariner first reported a position in IRulya Therapeutics Inc. Common Stock in Q3 2023 and held it in 10 quarters.
Mariner's IRulya Therapeutics Inc. Common Stock position peaked at $229K in Q4 2024.
26 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.